bf/NASDAQ:ZNTL_icon.jpeg

NASDAQ:ZNTL

Zentalis Pharmaceuticals, Inc.

  • Stock

USD

Last Close

1.30

06/11 21:01

Market Cap

279.79M

Beta: 1.83

Volume Today

680.48K

Avg: 602.77K

PE Ratio

−2.91

PFCF: −3.94

OverviewFinancialsAPI

    Description

    Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial ...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -3-2.5-2-1.5-1-0.50.52019-03-302019-12-312021-08-122023-05-102024-08-072025-05-05

    Revenue (Estimate*)

    10M20M30M40M2019-03-302019-12-312021-08-122023-05-102024-08-072025-05-05

    *Estimate based on analyst consensus